CLVTClarivate Plc

1. Oct 6, 2026On October 6, 2026, Clarivate Plc (“Clarivate”) completed the previously announced sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC (“Buyer”) pursuant to the Stock and Asset Purchase Agreement (the “Purchase Agreement”), dated as of July 3, 2026, between certain subsidiaries of …Acquisition or disposition completed · Form 8-K
2. Sep 24, 2026On September 24, 2026, Clarivate Plc issued a press release announcing the expiration and results of the previously announced cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities.Other event · Form 8-K
3. Sep 23, 2026On September 23, 2026, Clarivate Plc issued a press release announcing the pricing terms of the previously announced cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities.Other event · Form 8-K
4. Sep 17, 2026On September 17, 2026, Clarivate Plc issued a press release announcing the launch of cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities.Other event · Form 8-K
5. Jul 29, 2026Change in Chief Financial Officer On July 24, 2026, Jonathan Collins, the Executive Vice President & Chief Financial Officer of Clarivate Plc (the “Company”) resigned from his position, effective August 7, 2026.Director or officer change · Form 8-K
6. Jul 29, 2026Clarivate Reports Second Quarter 2026 Results.Earnings release · press release
7. Jul 6, 2026Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million.Regulation FD disclosure · press release
8. Jul 6, 2026On July 3, 2026, certain subsidiaries of Clarivate Plc (“Clarivate” or the “Company”) entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with an affiliate of Altaris, LLC (“Buyer”), pursuant to which, among other things, Clarivate has agreed to sell its Life Sciences and Healthcare business …Material agreement entered · Form 8-K
9. Jun 8, 2026Maroun S. Mourad, President, Intellectual Property of Clarivate Plc (the “Company”) will depart from his position, effective June 9, 2026. Following such date, Mr. Mourad will remain employed by the Company in a non-executive advisory role until September 30, 2026.Director or officer change · Form 8-K
10. May 18, 2026Date of 2027 Annual General Meeting of Shareholders Clarivate’s 2027 Annual General Meeting of Shareholders will be held on May 6, 2027. Further details will be provided in the proxy statement for the meeting.Shareholder vote results · Form 8-K
11. Apr 29, 2026Clarivate Reports First Quarter 2026 Results.Earnings release · press release
12. Mar 26, 2026On March 23, 2026, the Board of Directors (the “Board”) of Clarivate Plc (the “Company”), upon the recommendation of the Human Resources and Compensation Committee of the Board (the “HRCC”), approved the adoption of the Amended and Restated Executive Severance Plan of Clarivate Plc (the “A&R Executive Severance …Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.